LAM add-on ADV combination therapy or ETV monotherapy for CHB patients with suboptimal response to ADV.

Hongyu Jia,Feng Ding,Jianyang Chen,Yimin Zhang,Dairong Xiang,Jiangshan Lian,Linyan Zeng,Liang Yu,Jianhua Hu,Yongtao Li,Yingfeng Lu,Yuanchun Liu,Lin Zheng,Lanjuan Li,Yida Yang
DOI: https://doi.org/10.1016/S1665-2681(19)30779-3
IF: 3.388
2015-01-01
Annals of Hepatology
Abstract:Introduction. Among the available nucleos(t)ide analogues adefovir dipivoxil (ADV) is relatively cheap and widely used in rural area in China. However, there are insufficient data on recommendation for patients with suboptimal response to ADV after 48 weeks of treatment in order to reduce the resistance rate in the long term. The aim of this study was to compare the efficacy and safety of LAM add-on combination therapy versus ETV monotherapy for patients with suboptimal response to ADV.
What problem does this paper attempt to address?